Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma

A. Ottaiano, R. Tambaro, S. Greggi, R. Prato, M. Di Maio, G. Esposito, F. Scala, E. Barletta, S. Losito, R. De Vivo, Vr Iaffaioli, S. Pignata

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Carboplatin is a milestone drug against ovarian carcinoma; it is used both in front-line and second-line chemotherapy. Hypersensitivity reactions to carboplatin may occur during the treatment as salvage therapy. The purpose of this study was to describe the feasibility of the replacing of carboplatin with cisplatin in patients presenting with severe hypersensitivity reactions to carboplatin. Patients and Methods: Ten consecutive patients with platinum -sensitive, recurrent ovarian carcinoma, presenting with moderate/severe hypersensitivity reactions to carboplatin were treated with cisplatin 60 mg/m2 from January 2000 to December 2002. Hypersensitivity reactions consisted of respiratory distress (chest tightness, wheezing, dyspnea), urticaria/erythema with tachycardia, facial swelling and hypotension. Results: The total number of cisplatin cycles given was 44 (range 2-5). The treatment with cisplatin was generally well tolerated. No serious allergic reactions occurred. A mild allergic reaction was recorded (urticaria) in only one case, after one cycle of cisplatin, and the patient was not rechallenged because of progressive disease. No reductions of chemotherapy doses were needed. Conclusion: To date, platinum-based regimens remain the most effective treatment in recurrent platinum-sensitive ovarian cancer with a high rate of objective responses. Although our experience is limited, we suggest that, under anesthesiologic surveillance and providing immunologic blockade, the replacement of carboplatin salvage therapy with cisplatin can be considered a safe therapeutic strategy in patients who cannot continue carboplatin due to allergic reactions.

Original languageEnglish
Pages (from-to)3465-3468
Number of pages4
JournalAnticancer Research
Volume23
Issue number4
Publication statusPublished - Jul 2003

Fingerprint

Carboplatin
Cisplatin
Hypersensitivity
Carcinoma
Safety
Platinum
Salvage Therapy
Urticaria
Immunologic Surveillance
Drug Therapy
Respiratory Sounds
Therapeutics
Erythema
Tachycardia
Dyspnea
Ovarian Neoplasms
Hypotension
Thorax
Pharmaceutical Preparations

Keywords

  • Carboplatin
  • Cisplatin
  • Hypersensitivity reactions
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. / Ottaiano, A.; Tambaro, R.; Greggi, S.; Prato, R.; Di Maio, M.; Esposito, G.; Scala, F.; Barletta, E.; Losito, S.; De Vivo, R.; Iaffaioli, Vr; Pignata, S.

In: Anticancer Research, Vol. 23, No. 4, 07.2003, p. 3465-3468.

Research output: Contribution to journalArticle

@article{c28443daf7dc43b5b15cc1d413650b91,
title = "Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma",
abstract = "Background: Carboplatin is a milestone drug against ovarian carcinoma; it is used both in front-line and second-line chemotherapy. Hypersensitivity reactions to carboplatin may occur during the treatment as salvage therapy. The purpose of this study was to describe the feasibility of the replacing of carboplatin with cisplatin in patients presenting with severe hypersensitivity reactions to carboplatin. Patients and Methods: Ten consecutive patients with platinum -sensitive, recurrent ovarian carcinoma, presenting with moderate/severe hypersensitivity reactions to carboplatin were treated with cisplatin 60 mg/m2 from January 2000 to December 2002. Hypersensitivity reactions consisted of respiratory distress (chest tightness, wheezing, dyspnea), urticaria/erythema with tachycardia, facial swelling and hypotension. Results: The total number of cisplatin cycles given was 44 (range 2-5). The treatment with cisplatin was generally well tolerated. No serious allergic reactions occurred. A mild allergic reaction was recorded (urticaria) in only one case, after one cycle of cisplatin, and the patient was not rechallenged because of progressive disease. No reductions of chemotherapy doses were needed. Conclusion: To date, platinum-based regimens remain the most effective treatment in recurrent platinum-sensitive ovarian cancer with a high rate of objective responses. Although our experience is limited, we suggest that, under anesthesiologic surveillance and providing immunologic blockade, the replacement of carboplatin salvage therapy with cisplatin can be considered a safe therapeutic strategy in patients who cannot continue carboplatin due to allergic reactions.",
keywords = "Carboplatin, Cisplatin, Hypersensitivity reactions, Ovarian cancer",
author = "A. Ottaiano and R. Tambaro and S. Greggi and R. Prato and {Di Maio}, M. and G. Esposito and F. Scala and E. Barletta and S. Losito and {De Vivo}, R. and Vr Iaffaioli and S. Pignata",
year = "2003",
month = "7",
language = "English",
volume = "23",
pages = "3465--3468",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma

AU - Ottaiano, A.

AU - Tambaro, R.

AU - Greggi, S.

AU - Prato, R.

AU - Di Maio, M.

AU - Esposito, G.

AU - Scala, F.

AU - Barletta, E.

AU - Losito, S.

AU - De Vivo, R.

AU - Iaffaioli, Vr

AU - Pignata, S.

PY - 2003/7

Y1 - 2003/7

N2 - Background: Carboplatin is a milestone drug against ovarian carcinoma; it is used both in front-line and second-line chemotherapy. Hypersensitivity reactions to carboplatin may occur during the treatment as salvage therapy. The purpose of this study was to describe the feasibility of the replacing of carboplatin with cisplatin in patients presenting with severe hypersensitivity reactions to carboplatin. Patients and Methods: Ten consecutive patients with platinum -sensitive, recurrent ovarian carcinoma, presenting with moderate/severe hypersensitivity reactions to carboplatin were treated with cisplatin 60 mg/m2 from January 2000 to December 2002. Hypersensitivity reactions consisted of respiratory distress (chest tightness, wheezing, dyspnea), urticaria/erythema with tachycardia, facial swelling and hypotension. Results: The total number of cisplatin cycles given was 44 (range 2-5). The treatment with cisplatin was generally well tolerated. No serious allergic reactions occurred. A mild allergic reaction was recorded (urticaria) in only one case, after one cycle of cisplatin, and the patient was not rechallenged because of progressive disease. No reductions of chemotherapy doses were needed. Conclusion: To date, platinum-based regimens remain the most effective treatment in recurrent platinum-sensitive ovarian cancer with a high rate of objective responses. Although our experience is limited, we suggest that, under anesthesiologic surveillance and providing immunologic blockade, the replacement of carboplatin salvage therapy with cisplatin can be considered a safe therapeutic strategy in patients who cannot continue carboplatin due to allergic reactions.

AB - Background: Carboplatin is a milestone drug against ovarian carcinoma; it is used both in front-line and second-line chemotherapy. Hypersensitivity reactions to carboplatin may occur during the treatment as salvage therapy. The purpose of this study was to describe the feasibility of the replacing of carboplatin with cisplatin in patients presenting with severe hypersensitivity reactions to carboplatin. Patients and Methods: Ten consecutive patients with platinum -sensitive, recurrent ovarian carcinoma, presenting with moderate/severe hypersensitivity reactions to carboplatin were treated with cisplatin 60 mg/m2 from January 2000 to December 2002. Hypersensitivity reactions consisted of respiratory distress (chest tightness, wheezing, dyspnea), urticaria/erythema with tachycardia, facial swelling and hypotension. Results: The total number of cisplatin cycles given was 44 (range 2-5). The treatment with cisplatin was generally well tolerated. No serious allergic reactions occurred. A mild allergic reaction was recorded (urticaria) in only one case, after one cycle of cisplatin, and the patient was not rechallenged because of progressive disease. No reductions of chemotherapy doses were needed. Conclusion: To date, platinum-based regimens remain the most effective treatment in recurrent platinum-sensitive ovarian cancer with a high rate of objective responses. Although our experience is limited, we suggest that, under anesthesiologic surveillance and providing immunologic blockade, the replacement of carboplatin salvage therapy with cisplatin can be considered a safe therapeutic strategy in patients who cannot continue carboplatin due to allergic reactions.

KW - Carboplatin

KW - Cisplatin

KW - Hypersensitivity reactions

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0043030090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043030090&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 3465

EP - 3468

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -